Study Links GLP-1 Weight-Loss Medications to Rare Brain Disorder

The study utilized data from the FDA's Adverse Event Reporting System (FAERS), existing medical literature, and information from their own medical center. Many patients reported gastrointestinal symptoms or nutritional deficiencies, including weight loss, vomiting, and loss of appetite.

Researchers noted that reports of Wernicke encephalopathy were more frequent among GLP-1 medication users compared to individuals on other treatments. However, they cautioned that the study does not establish a causal relationship between the medications and the disorder.

Vitamin B1 is crucial for brain function, and its severe deficiency can lead to symptoms such as confusion, balance issues, and vision changes. If untreated, Wernicke encephalopathy can result in permanent neurological damage or death.

Karthik Achari, a clinician based in Chicago, stated that the findings should be seen in context. He pointed out that while 15 cases were identified, this figure is minimal compared to the millions using these medications. Achari also highlighted that while GLP-1 medications can suppress appetite, they may lead to vitamin B1 deficiency due to decreased food intake, as the body’s nutritional requirements remain unchanged.

Erin Palinski-Wade, a nutritionist in New Jersey, stressed the importance of maintaining proper nutrition and hydration during GLP-1 therapy. She warned that ongoing symptoms like vomiting could increase risks of dehydration and other health issues and advised patients to seek medical advice for severe or enduring symptoms.

The researchers acknowledged the limitations of their study, which largely relied on reported cases, and called for further research. They advised that patients should not discontinue GLP-1 medications solely based on these findings.